MARKET

GUTS

GUTS

Fractyl Health
NASDAQ
2.040
+0.060
+3.03%
After Hours: 2.030 -0.01 -0.49% 19:40 12/05 EST
OPEN
2.010
PREV CLOSE
1.980
HIGH
2.115
LOW
1.955
VOLUME
4.51M
TURNOVER
--
52 WEEK HIGH
3.030
52 WEEK LOW
0.8250
MARKET CAP
279.57M
P/E (TTM)
-0.8968
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 8h ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 11h ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 1d ago
Promising Data and Future Prospects Lead to Buy Rating for Fractyl Health, Inc.
TipRanks · 2d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 3d ago
Fractyl Health's Revita Procedure Helps Patients Keep Weight Off After Stopping GLP-1 Drugs
Benzinga · 3d ago
Fractyl Health Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
Fractyl Health says procedure can maintain weight loss after stopping GLP-1
Seeking Alpha · 3d ago
More
About GUTS
Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.

Webull offers Fractyl Health Inc stock information, including NASDAQ: GUTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GUTS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GUTS stock methods without spending real money on the virtual paper trading platform.